Active Pharmaceutical Ingredients

Active Pharmaceutical Ingredients (API) Market (Manufacturer - In house API Manufacturing, API Contract Manufacturing; APIs - Synthetic Chemical API, Biotech or Biological API, Plant Extracts API, High-potency API, Classical Fermentation API; Drug - Branded or Innovative Prescription Drugs, Generic Prescription Drugs, OTC (Over-the-counter) Drugs; Therapeutic - Anti-infective Drugs, Metabolic Disorders Drugs, Cardiovascular Drugs, Respiratory Diseases Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018–2026

  • Rep Id : TMRGL1690
  • Published On : Nov 2018
  • No. of Pages : 190
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Active Pharmaceutical Ingredients (API)

4. Market Overview
     4.1. Introduction
            4.1.1. Type of Manufacturers Definition
            4.1.2. Industry Evolution/Developments
     4.2.  Overview
     4.3. Market Dynamics
            4.3.1. Drivers
                     4.3.1.1. Increase in Abbreviated New Drug Applications (ANDA) in the Recent Past Boosted the Demand for APIs
                     4.3.1.2. Increasing Government Prioritization for  Biomedical Innovation
                     4.3.1.3. Increase in Drug Master File (DMF) Filing from Indian and Chinese Companies Indicates a Rapid API market growth
                     4.3.1.4. Increasing Incidence of Acute and Chronic Diseases
                     4.3.1.5. Increasing Biopharmaceuticals Uptake Globally
            4.3.2. Restraints
                     4.3.2.1.Strict European Union Regulatory Policies Restraining Market Growth 
                     4.3.2.2. Unfavorable Drug Price Control Policies 
            4.3.3. Opportunities
            4.3.4. Key Trends
                     4.3.4.1. Biologics Expected to be Key Pipeline Trend
                     4.3.4.2. Increase in Focus on Research & Development
                     4.3.4.3. Shift from Branded to Generics
                     4.3.4.4. Governments Encouraging Development of Orphan Drugs
     4.4. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Value Chain Analysis
     5.2. Patent Expiry of Major Drugs in 2018
     5.3. Patent Expiry of Major Drugs in 2019 & 2020

6. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Manufacturers 
     6.1. Introduction & Definition
     6.2. Key Findings/Developments
     6.3. Market Value  Forecast by Type of Manufacturers, 2016–2026
            6.3.1. In-house API Manufacturing
            6.3.2. API Contract Manufacturing
     6.4. Market Attractiveness, by Type of Manufacturers 

7. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of APIs 
     7.1. Introduction & Definition
     7.2. Key Findings/Developments
     7.3. Market Value  Forecast, by Type of APIs, 2016–2026
            7.3.1. Synthetic Chemical API
            7.3.2. Biotech/Biological API
            7.3.3. Plant Extracts API
            7.3.4. High-potency API
            7.3.5. Classical Fermentation API
     7.4. Market Attractiveness, by Type of APIs 

8. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Drug 
     8.1. Introduction & Definition
     8.2. Key Findings/Developments
     8.3. Market Value  Forecast, by Type of Drug, 2016–2026
            8.3.1. Branded or Innovative Prescription Drugs
            8.3.2. Generic Prescription Drugs
            8.3.3. Over-the-counter (OTC) Drugs
            8.3.4. Others
     8.4. Market Attractiveness, by Type of Drug 

9. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Therapeutic 
     9.1. Introduction & Definition
     9.2. Key Findings/Developments
     9.3. Market Value  Forecast, by Therapeutic, 2016–2026
            9.3.1. Anti-infective Drugs
            9.3.2. Metabolic Disorders Drugs
            9.3.3. Cardiovascular Drugs
            9.3.4. Oncology Drugs
            9.3.5. Central Nervous System Drugs
            9.3.6. Respiratory Diseases Drugs
            9.3.7. Others
     9.4. Market Attractiveness, by Therapeutic 

10. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Region
     10.1. Key Findings
     10.2. Market Value  Forecast by Region
            10.2.1. North America 
            10.2.2. Europe 
            10.2.3. Asia Pacific 
            10.2.4. Latin America 
            10.2.5. Middle East & Africa 
     10.3. Market Attractiveness, by Region

11. North America Active Pharmaceutical Ingredients (API) Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value  Forecast, by Type of Manufacturers, 2016–2026
            11.2.1. In-house API Manufacturing
            11.2.2. API Contract Manufacturing
     11.3.Market Value  Forecast, by Type of APIs, 2016–2026
            11.3.1. Synthetic Chemical API
            11.3.2. Biotech/Biological API
            11.3.3. Plant Extracts API
            11.3.4. High-potency API
            11.3.5. Classical Fermentation API
     11.4.Market Value  Forecast, by Type of Drug, 2016–2026
            11.4.1. Branded or Innovative Prescription Drugs
            11.4.2. Generic Prescription Drugs
            11.4.3. over-the-counter (OTC) Drugs
11.4.4. Others
     11.5.Market Value  Forecast, by Therapeutic, 2016–2026
            11.5.1. Anti-infective Drugs
            11.5.2. Metabolic Disorders Drugs
            11.5.3. Cardiovascular Drugs
            11.5.4. Oncology Drugs
            11.5.5. Central Nervous System Drugs
            11.5.6. Respiratory Diseases Drugs
            11.5.7. Others
     11.6.Market Value  Forecast, by Country, 2016–2026
            11.6.1. U.S.
            11.6.2. Canada
     11.7.Market Attractiveness Analysis 
            11.7.1. By Type of Manufacturers 
            11.7.2. By Type of APIs 
            11.7.3. By Type of Drug 
            11.7.4. By Therapeutic 
            11.7.5. By Country

12. Europe Active Pharmaceutical Ingredients (API) Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value  Forecast, by Type of Manufacturers, 2016–2026
            12.2.1. In-house API Manufacturing
            12.2.2. API Contract Manufacturing
     12.3.Market Value  Forecast, by Type of APIs, 2016–2026
            12.3.1. Synthetic Chemical API
            12.3.2. Biotech/Biological API
            12.3.3. Plant Extracts API
            12.3.4. High-potency API
            12.3.5. Classical Fermentation API
     12.4.Market Value  Forecast, by Type of Drug, 2016–2026
            12.4.1. Branded or Innovative Prescription Drugs
            12.4.2. Generic Prescription Drugs
            12.4.3. Over-the-counter (OTC) Drugs
            12.4.4. Others
     12.5.Market Value  Forecast, by Therapeutic, 2016–2026
            12.5.1. Anti-infective Drugs
            12.5.2. Metabolic Disorders Drugs
            12.5.3. Cardiovascular Drugs
            12.5.4. Oncology Drugs
            12.5.5. Central Nervous System Drugs
            12.5.6. Respiratory Diseases Drugs
            12.5.7. Others
     12.6.Market Value  Forecast, by Country/Sub-region, 2016–2026
            12.6.1. Germany
            12.6.2. U.K.
            12.6.3. France
            12.6.4. Spain
            12.6.5. Italy
            12.6.6. Rest of Europe
     12.7.Market Attractiveness Analysis 
            12.7.1. By Type of Manufacturers 
            12.7.2. By Type of APIs 
            12.7.3. By Type of Drug 
            12.7.4. By Therapeutic 
            12.7.5. By Country/Sub-region

13. Asia Pacific Active Pharmaceutical Ingredients (API) Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value  Forecast, by Type of Manufacturers, 2016–2026
            13.2.1. In-house API Manufacturing
            13.2.2. API Contract Manufacturing
     13.3.Market Value  Forecast, by Type of APIs, 2016–2026
            13.3.1. Synthetic Chemical API
            13.3.2. Biotech/Biological API
            13.3.3. Plant Extracts API
            13.3.4. High-potency API
            13.3.5. Classical Fermentation API
     13.4.Market Value  Forecast, by Type of Drug, 2016–2026
            13.4.1. Branded or Innovative Prescription Drugs
            13.4.2. Generic Prescription Drugs
            13.4.3. Over-the-counter (OTC) Drugs
            13.4.4. Others
     13.5.Market Value  Forecast, by Therapeutic, 2016–2026
            13.5.1. Anti-infective Drugs
            13.5.2. Metabolic Disorders Drugs
            13.5.3. Cardiovascular Drugs
            13.5.4. Oncology Drugs
            13.5.5. Central Nervous System Drugs
            13.5.6. Respiratory Diseases Drugs
            13.5.7. Others
     13.6.Market Value  Forecast, by Country/Sub-region, 2016–2026
            13.6.1. China
            13.6.2. Japan
            13.6.3. India
            13.6.4. Australia & New Zealand
            13.6.5. Rest of Asia Pacific
     13.7.Market Attractiveness Analysis 
            13.7.1. By Type of Manufacturers 
            13.7.2. By Type of APIs 
            13.7.3. By Type of Drug 
            13.7.4. By Therapeutic 
            13.7.5. By Country/Sub-region

14. Latin America Active Pharmaceutical Ingredients (API) Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2.Market Value  Forecast, by Type of Manufacturers, 2016–2026
            14.2.1. In-house API Manufacturing
            14.2.2. API Contract Manufacturing
     14.3.Market Value  Forecast, by Type of APIs, 2016–2026
            14.3.1. Synthetic Chemical API
            14.3.2. Biotech/Biological API
            14.3.3. Plant Extracts API
            14.3.4. High-potency API
            14.3.5. Classical Fermentation API
     14.4.Market Value  Forecast, by Type of Drug, 2016–2026
            14.4.1. Branded or Innovative Prescription Drugs
            14.4.2. Generic Prescription Drugs
            14.4.3. Over-the-counter (OTC) Drugs
            14.4.4. Others
     14.5.Market Value  Forecast, by Therapeutic, 2016–2026
            14.5.1. Anti-infective Drugs
            14.5.2. Metabolic Disorders Drugs
            14.5.3. Cardiovascular Drugs
            14.5.4. Oncology Drugs
            14.5.5. Central Nervous System Drugs
            14.5.6. Respiratory Diseases Drugs
            14.5.7. Others
     14.6.Market Value  Forecast, by Country/Sub-region, 2016–2026
            14.6.1. Brazil
            14.6.2. Mexico
            14.6.3. Rest of Latin America
     14.7.Market Attractiveness Analysis 
            14.7.1. By Type of Manufacturers 
            14.7.2. By Type of APIs 
            14.7.3. By Type of Drug 
            14.7.4. By Therapeutic 
            14.7.5. By Country/Sub-region

15. Middle East & Africa Active Pharmaceutical Ingredients (API) Analysis and Forecast
     15.1.Introduction
            15.1.1. Key Findings
            15.2.Market Value  Forecast, by Type of Manufacturers, 2016–2026
     15.2.1. In-house API Manufacturing
            15.2.2. API Contract Manufacturing
     15.3.Market Value  Forecast, by Type of APIs, 2016–2026
            15.3.1. Synthetic Chemical API
            15.3.2. Biotech/Biological API
            15.3.3. Plant Extracts API
            15.3.4. High-potency API
            15.3.5. Classical Fermentation API
     15.4.Market Value  Forecast, by Type of Drug, 2016–2026
            15.4.1. Branded or Innovative Prescription Drugs
            15.4.2. Generic Prescription Drugs
            15.4.3. Over-the-counter (OTC) Drugs
            15.4.4. Others
     15.5.Market Value  Forecast, by Therapeutic, 2016–2026
            15.5.1. Anti-infective Drugs
            15.5.2. Metabolic Disorders Drugs
            15.5.3. Cardiovascular Drugs
            15.5.4. Oncology Drugs
            15.5.5. Central Nervous System Drugs
            15.5.6. Respiratory Diseases Drugs
            15.5.7. Others
     15.6.Market Value  Forecast, by Country/Sub-region, 2016–2026
            15.6.1. GCC Countries
            15.6.2. South Africa
            15.6.3. Israel
            15.6.4. Rest of Middle East & Africa
     15.7.Market Attractiveness Analysis 
            15.7.1. By Type of Manufacturers 
            15.7.2. By Type of APIs 
            15.7.3. By Type of Drug 
            15.7.4. By Therapeutic 
            15.7.5. By Country/Sub-region

16. Competition Landscape
     16.1.Market Player – Competition Matrix (By Tier and Size of companies)
     16.2.Market Share Analysis, by Company (2017)
     16.5. Company Profiles
            16.5.1. Teva Pharmaceutical Industries Ltd.
            16.5.2. Sun Pharmaceutical Industries Ltd.
            16.5.3. Aurobindo Pharma
            16.5.4. Pfizer Inc.
            16.5.5. Boehringer Ingelheim International GmbH.
            16.5.6. Merck & Co., Inc.
            16.5.7. Novartis AG
            16.5.8. F. Hoffmann-La Roche Ltd
            16.5.9. Bayer AG
            16.5.10. Others

List of Tables

Table 01: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016–2026
Table 02: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 04: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 05: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 06: Patent Expiry of Major Drugs in 2018
Table 07: Patent Expiry of Major Drugs in 2019 & 2020
Table 08 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016–2026
Table 09 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 10 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 11 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 12 : North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country 2016–2026
Table 13 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016–2026
Table 14 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 15 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 16 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 17 : Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
Table 18 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016–2026
Table 19 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 20 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 21 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 22 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 23 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016–2026
Table 24 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 25 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 26 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 27 : Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 28 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016–2026
Table 29 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016–2026
Table 30 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016–2026
Table 31 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016–2026
Table 32 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

List of Figures

Figure 01: Active Pharmaceutical Ingredients (API) Market Snapshot
Figure 02: Executive Summary
Figure 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn), CAGR (%), and Market Share (%), by Region, 2018 and 2026
Figure 04: Key Market Developments
Figure 05: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 06: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 07: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 08: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 09: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 10: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 11: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 12: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 13: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 14: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Region, 2018 and 2026
Figure 15: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Region, 2018–2026
Figure 16 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 17 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 18 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 19 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 20 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 21 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 22 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 23 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 24 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 25 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Country, 2018 and 2026
Figure 26 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2018–2026
Figure 27 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 28 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 29 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 30 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 31 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 32 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 33 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 34 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 35 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 36 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 37 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 38 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 39 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 40 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 41 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 42 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 43 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 44 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 45 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 46 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 47 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 48 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 49 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 50 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 51 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 52 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 53 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 54 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 55 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 56 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 57 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 58 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 59 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 60 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016–2026
Figure 61 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
Figure 62 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018–2026
Figure 63 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
Figure 64 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018–2026
Figure 65 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
Figure 66 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018–2026
Figure 67 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
Figure 68 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018–2026
Figure 69 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
Figure 70 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018–2026

.